vs
Side-by-side financial comparison of Fidelity National Financial, Inc. (FNF) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Fidelity National Financial, Inc. is the larger business by last-quarter revenue ($544.0M vs $281.3M, roughly 1.9× Guardant Health, Inc.). Fidelity National Financial, Inc. runs the higher net margin — -21.5% vs -45.7%, a 24.2% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 10.3%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 13.7%).
Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
FNF vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $544.0M | $281.3M |
| Net Profit | $-117.0M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | 82.9% | -43.0% |
| Net Margin | -21.5% | -45.7% |
| Revenue YoY | 10.3% | 39.4% |
| Net Profit YoY | -126.0% | -15.8% |
| EPS (diluted) | $-0.44 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $544.0M | $281.3M | ||
| Q3 25 | $553.0M | $265.2M | ||
| Q2 25 | $547.0M | $232.1M | ||
| Q1 25 | $455.0M | $203.5M | ||
| Q4 24 | $493.0M | $201.8M | ||
| Q3 24 | $506.0M | $191.5M | ||
| Q2 24 | $504.0M | $177.2M | ||
| Q1 24 | $421.0M | $168.5M |
| Q4 25 | $-117.0M | $-128.5M | ||
| Q3 25 | $358.0M | $-92.7M | ||
| Q2 25 | $278.0M | $-99.9M | ||
| Q1 25 | $83.0M | $-95.2M | ||
| Q4 24 | $450.0M | $-111.0M | ||
| Q3 24 | $266.0M | $-107.8M | ||
| Q2 24 | $306.0M | $-102.6M | ||
| Q1 24 | $248.0M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | 82.9% | -43.0% | ||
| Q3 25 | 81.9% | -37.3% | ||
| Q2 25 | 69.8% | -45.9% | ||
| Q1 25 | 24.4% | -54.6% | ||
| Q4 24 | — | -62.4% | ||
| Q3 24 | 61.9% | -61.3% | ||
| Q2 24 | 90.9% | -56.8% | ||
| Q1 24 | 78.6% | -59.2% |
| Q4 25 | -21.5% | -45.7% | ||
| Q3 25 | 64.7% | -35.0% | ||
| Q2 25 | 50.8% | -43.0% | ||
| Q1 25 | 18.2% | -46.8% | ||
| Q4 24 | 91.3% | -55.0% | ||
| Q3 24 | 52.6% | -56.3% | ||
| Q2 24 | 60.7% | -57.9% | ||
| Q1 24 | 58.9% | -68.2% |
| Q4 25 | $-0.44 | $-1.01 | ||
| Q3 25 | $1.33 | $-0.74 | ||
| Q2 25 | $1.02 | $-0.80 | ||
| Q1 25 | $0.30 | $-0.77 | ||
| Q4 24 | $1.65 | $-0.90 | ||
| Q3 24 | $0.97 | $-0.88 | ||
| Q2 24 | $1.12 | $-0.84 | ||
| Q1 24 | $0.91 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.6B | $378.2M |
| Total DebtLower is stronger | $4.4B | $1.5B |
| Stockholders' EquityBook value | $7.4B | $-99.3M |
| Total Assets | $109.0B | $2.0B |
| Debt / EquityLower = less leverage | 0.59× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.6B | $378.2M | ||
| Q3 25 | $3.5B | $580.0M | ||
| Q2 25 | $3.3B | $629.1M | ||
| Q1 25 | $4.5B | $698.6M | ||
| Q4 24 | $3.5B | $525.5M | ||
| Q3 24 | $5.0B | $585.0M | ||
| Q2 24 | $4.9B | $933.7M | ||
| Q1 24 | $3.5B | $1.0B |
| Q4 25 | $4.4B | $1.5B | ||
| Q3 25 | $4.4B | $1.1B | ||
| Q2 25 | $4.4B | $1.1B | ||
| Q1 25 | $4.4B | $1.1B | ||
| Q4 24 | $4.3B | $1.1B | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $4.2B | — | ||
| Q1 24 | $3.9B | — |
| Q4 25 | $7.4B | $-99.3M | ||
| Q3 25 | $8.4B | $-354.5M | ||
| Q2 25 | $7.9B | $-305.5M | ||
| Q1 25 | $7.9B | $-250.8M | ||
| Q4 24 | $7.8B | $-139.6M | ||
| Q3 24 | $8.1B | $-60.1M | ||
| Q2 24 | $7.3B | $-1.6M | ||
| Q1 24 | $7.1B | $68.3M |
| Q4 25 | $109.0B | $2.0B | ||
| Q3 25 | $106.6B | $1.3B | ||
| Q2 25 | $102.3B | $1.3B | ||
| Q1 25 | $98.2B | $1.3B | ||
| Q4 24 | $95.4B | $1.5B | ||
| Q3 24 | $94.7B | $1.5B | ||
| Q2 24 | $88.8B | $1.6B | ||
| Q1 24 | $84.5B | $1.7B |
| Q4 25 | 0.59× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.56× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.56× | — | ||
| Q3 24 | 0.52× | — | ||
| Q2 24 | 0.58× | — | ||
| Q1 24 | 0.55× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.5B | $-26.4M |
| Free Cash FlowOCF − Capex | — | $-54.2M |
| FCF MarginFCF / Revenue | — | -19.3% |
| Capex IntensityCapex / Revenue | — | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5B | $-26.4M | ||
| Q3 25 | $1.3B | $-35.4M | ||
| Q2 25 | $1.9B | $-60.3M | ||
| Q1 25 | $1.1B | $-62.7M | ||
| Q4 24 | $1.5B | $-64.5M | ||
| Q3 24 | $2.4B | $-51.1M | ||
| Q2 24 | $1.4B | $-94.0M | ||
| Q1 24 | $1.6B | $-30.3M |
| Q4 25 | — | $-54.2M | ||
| Q3 25 | — | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M | ||
| Q1 24 | — | $-37.2M |
| Q4 25 | — | -19.3% | ||
| Q3 25 | — | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% | ||
| Q1 24 | — | -22.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | 3.66× | — | ||
| Q2 25 | 6.82× | — | ||
| Q1 25 | 13.43× | — | ||
| Q4 24 | 3.32× | — | ||
| Q3 24 | 8.89× | — | ||
| Q2 24 | 4.45× | — | ||
| Q1 24 | 6.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNF
| Escrow Fees | $241.0M | 44% |
| Other Title Related Fees And Income | $182.0M | 33% |
| Service Link Excluding Title Premiums Escrow Fees And Subservicing Fees | $87.0M | 16% |
| Insurance Contracts Home Warranty | $31.0M | 6% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
